ADA Scientific Sessions 2026 Abstract
Continuous Glucose Monitoring in Type 2 Diabetes Managed with Basal Insulin plus SGLT2 Inhibitor and/or GLP-1 Agonist: Subgroup Analysis from the FreeDM2 Trial
By Lalantha Leelarathna, Patrick J. Moore, Thozhukat Sathyapalan, Show 21 more authorsFreedm2 Study Group
Trial in peopleInterventions
The paper
London
ADA Scientific Sessions 2026 Abstract, 6 Jun 2026
Presented at ADA Scientific Sessions 2026, oral 1174-OR